DelveInsight recently conducted an in-depth MASH Market Size and Share Assessment to help a pharmaceutical client understand the ...
DelveInsight's "ROZLYTREK Market Size, Forecast, and Market Insight Report" highlights the details around ROZLYTREK, an ...
Gilead Sciences, Inc. today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference on Retroviruses ...
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...
Gilead Sciences, Inc. today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company's injectable HIV-1 capsid inhibitor, ...
Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of ...
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Gilead (GILD) to $130 from $123 and keeps an Overweight rating on the ...
WeDriveU Customers Named Best Workplaces and Best Universities for Commuters in 2025 WeDriveU logo Annual award program honors emplo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results